universal CLL1 CAR-T cells

Universal CLL1 CAR-T cells are an allogeneic, "off-the-shelf" chimeric antigen receptor (CAR) T-cell therapy designed to target C-type lectin-like molecule 1 (CLL-1, also known as CLEC12A). Developed by Mingfeng Zhao at Tianjin First Central Hospital, these cells are engineered using a specialized non-gene editing intracellular membrane protein retention technology. This platform allows for the creation of universal CAR-T cells without the need for traditional gene-editing tools like CRISPR/Cas9 to prevent Graft-versus-Host Disease (GvHD) and immune rejection. CLL-1 is a highly attractive target for acute myeloid leukemia (AML) as it is expressed on over 90% of AML blasts and leukemic stem cells (LSCs) while being absent on normal hematopoietic stem cells, potentially allowing for the eradication of the disease while sparing healthy bone marrow function.

Other names

CLL1-UCARTCLL-1-UCARTCLL 1-UCARTallogeneic CLL1 CAR-T cellsUniversal CLL1 Chimeric Antigen Receptor T-Cell